Compare PulteGroup, Inc. (PHM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Sanofi SA — how do they compare? PulteGroup, Inc. trades at $118.95 (market cap $22.87B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 4.6× PulteGroup, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| PHM | SNY | |
|---|---|---|
Market Cap | $22.87B | $104.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $52.34 |
52-Week Low | $110.11 | $41.33 |
Enterprise Value | $23.28B | $124.09B |
Dividend Yield | 0.87% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.
The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
